While I believe Pfizer will rebound eventually, it will take some time to do so, and it may not occur in 2026. In the ...

There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at ...

Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major’s shares have gained ...

As of Friday, January 09, Allogene Therapeutics, Inc.’s ALLO share price has surged by 18.13%, which has investors questioning if this is right time to sell.

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

Dow Jones Industrial Average, Chevron Corp, Coca-Cola Co, Merck & Company Inc. Read 's Market Analysis on Investing.com ...

Biotech stocks have rallied strongly into 2026, building on the late-2025 momentum from positive clinical data, cheaper valuation, easy money policy and favorable macro conditions. Biotech-based ...

Madrigal Pharmaceuticals (MDGL) stock is in focus as the company licenses Pfizer’s (PFE) experimental MASH therapy ervogastat. Read more here.

Meanwhile, another $70 million to $80 million of IPO proceeds is expected to fund the launch a phase 1b study of its second ...

Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share, reflecting a 6.8% increase in ...

In 2025 alone, MSD acquired infectious disease specialist Cidara Therapeutics for $9.2 billion, respiratory drug developer ...